GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Gross Profit

ARDS (Aridis Pharmaceuticals) Gross Profit : $19.65 Mil (TTM As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Gross Profit?

Aridis Pharmaceuticals's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Aridis Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $19.65 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Aridis Pharmaceuticals's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Aridis Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Aridis Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 was N/A%.

Aridis Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Aridis Pharmaceuticals Gross Profit Historical Data

The historical data trend for Aridis Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Gross Profit Chart

Aridis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial 2.76 - - - -

Aridis Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 19.65 -

Competitive Comparison of Aridis Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Aridis Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aridis Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's Gross Profit falls into.



Aridis Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Aridis Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Aridis Pharmaceuticals's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.65 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Aridis Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Aridis Pharmaceuticals  (OTCPK:ARDS) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Aridis Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Aridis Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Aridis Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Executives
Vu Truong director, 10 percent owner, officer: CEO, CSO, Director 5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer director, 10 percent owner 5941 OPTICAL CT., SAN JOSE CA 95138
Fibrosis Foundation Cystic 10 percent owner 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri officer: Chief Medical Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
John F Hamilton director 1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak officer: Chief Financial Officer 5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland officer: Chief Financial Officer C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer officer: Chief Medical Officer 5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo director
Shawn Lu director C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin director 5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025